{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=8",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 20596,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T18:04:41.427Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00724867",
      "title": "A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Belimumab 1 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belimumab 10 mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Human Genome Sciences Inc., a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 268,
      "start_date": "2008-08",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-03-28",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00724867"
    },
    {
      "nct_id": "NCT00596154",
      "title": "Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CNS Lymphoma",
        "CNS Brain Cancer",
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 33,
      "start_date": "2004-12",
      "completion_date": "2023-02-02",
      "has_results": true,
      "last_update_posted_date": "2024-04-01",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 3,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00596154"
    },
    {
      "nct_id": "NCT02595866",
      "title": "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIDS-Related Non-Hodgkin Lymphoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Hepatocellular Carcinoma",
        "HIV Infection",
        "Kaposi Sarcoma",
        "Locally Advanced Lung Non-Small Cell Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Non-Hodgkin Lymphoma",
        "Recurrent Classic Hodgkin Lymphoma",
        "Recurrent Malignant Neoplasm",
        "Refractory Classic Hodgkin Lymphoma",
        "Refractory Malignant Neoplasm",
        "Stage III Lung Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Antiretroviral Therapy",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2016-04-04",
      "completion_date": "2024-03-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595866"
    },
    {
      "nct_id": "NCT05757856",
      "title": "A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "NDX-3315",
          "type": "DRUG"
        },
        {
          "name": "NDX-3324",
          "type": "DRUG"
        },
        {
          "name": "SPECT/CT Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "NexEos Diagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2023-01-20",
      "completion_date": "2025-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05757856"
    },
    {
      "nct_id": "NCT06915831",
      "title": "Type 1 Diabetes and Obstructive Sleep Apnea",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sleep Apnea, Obstructive",
        "Type 1 Diabetes (T1D)"
      ],
      "interventions": [
        {
          "name": "Continuous positive airway pressure (CPAP)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-11-10",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06915831"
    },
    {
      "nct_id": "NCT07298395",
      "title": "Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis (AD)"
      ],
      "interventions": [
        {
          "name": "ENV-294",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enveda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 105,
      "start_date": "2025-12-22",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07298395"
    },
    {
      "nct_id": "NCT00833495",
      "title": "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Prednisolone Acetate 0.12% (Pred Mild®)",
          "type": "DRUG"
        },
        {
          "name": "FOV1101-00",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1% (Pred Forte®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fovea Pharmaceuticals SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2009-01",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-09",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833495"
    },
    {
      "nct_id": "NCT00001677",
      "title": "Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid",
        "Synovitis"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "1998-06",
      "completion_date": "2000-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001677"
    },
    {
      "nct_id": "NCT05267600",
      "title": "A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Bullous Pemphigoid"
      ],
      "interventions": [
        {
          "name": "efgartigimod PH20 SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2022-06-09",
      "completion_date": "2024-09-13",
      "has_results": true,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Redwood City, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Castle Rock",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267600"
    },
    {
      "nct_id": "NCT04140305",
      "title": "Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "RPC-1063",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 188,
      "start_date": "2020-01-16",
      "completion_date": "2025-05-15",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-10-17T18:04:41.427Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140305"
    }
  ]
}